South Korea · Delayed Price · Currency is KRW HLB bioStep Statistics
Total Valuation
HLB bioStep has a market cap or net worth of KRW 54.22 billion. The enterprise value is 58.96 billion.
| Market Cap | 54.22B |
| Enterprise Value | 58.96B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HLB bioStep has 17.21 million shares outstanding. The number of shares has decreased by -44.94% in one year.
| Current Share Class | 17.21M |
| Shares Outstanding | 17.21M |
| Shares Change (YoY) | -44.94% |
| Shares Change (QoQ) | +244.95% |
| Owned by Insiders (%) | 1.01% |
| Owned by Institutions (%) | 1.02% |
| Float | 14.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.73 |
| PB Ratio | 0.50 |
| P/TBV Ratio | 0.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.06 |
| EV / Sales | 0.80 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -13.71 |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.29.
| Current Ratio | 1.20 |
| Quick Ratio | 0.95 |
| Debt / Equity | 0.29 |
| Debt / EBITDA | n/a |
| Debt / FCF | -7.20 |
| Interest Coverage | -3.65 |
Financial Efficiency
Return on equity (ROE) is -18.40% and return on invested capital (ROIC) is -8.88%.
| Return on Equity (ROE) | -18.40% |
| Return on Assets (ROA) | -3.47% |
| Return on Invested Capital (ROIC) | -8.88% |
| Return on Capital Employed (ROCE) | -7.64% |
| Weighted Average Cost of Capital (WACC) | 4.07% |
| Revenue Per Employee | 503.11M |
| Profits Per Employee | -131.13M |
| Employee Count | 147 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 11.24 |
Taxes
In the past 12 months, HLB bioStep has paid 2.41 billion in taxes.
| Income Tax | 2.41B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.60% in the last 52 weeks. The beta is -0.24, so HLB bioStep's price volatility has been lower than the market average.
| Beta (5Y) | -0.24 |
| 52-Week Price Change | -59.60% |
| 50-Day Moving Average | 5,638.20 |
| 200-Day Moving Average | 6,632.93 |
| Relative Strength Index (RSI) | 21.39 |
| Average Volume (20 Days) | 129,379 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, HLB bioStep had revenue of KRW 73.96 billion and -19.28 billion in losses. Loss per share was -1,085.34.
| Revenue | 73.96B |
| Gross Profit | 55.32B |
| Operating Income | -8.70B |
| Pretax Income | -18.13B |
| Net Income | -19.28B |
| EBITDA | -3.93B |
| EBIT | -8.70B |
| Loss Per Share | -1,085.34 |
Balance Sheet
The company has 30.79 billion in cash and 30.96 billion in debt, with a net cash position of -168.07 million or -9.76 per share.
| Cash & Cash Equivalents | 30.79B |
| Total Debt | 30.96B |
| Net Cash | -168.07M |
| Net Cash Per Share | -9.76 |
| Equity (Book Value) | 107.44B |
| Book Value Per Share | 5,975.78 |
| Working Capital | 8.00B |
Cash Flow
In the last 12 months, operating cash flow was -2.36 billion and capital expenditures -1.94 billion, giving a free cash flow of -4.30 billion.
| Operating Cash Flow | -2.36B |
| Capital Expenditures | -1.94B |
| Depreciation & Amortization | 4.77B |
| Net Borrowing | 604.57M |
| Free Cash Flow | -4.30B |
| FCF Per Share | -249.77 |
Margins
Gross margin is 74.80%, with operating and profit margins of -11.76% and -26.06%.
| Gross Margin | 74.80% |
| Operating Margin | -11.76% |
| Pretax Margin | -24.51% |
| Profit Margin | -26.06% |
| EBITDA Margin | -5.31% |
| EBIT Margin | -11.76% |
| FCF Margin | n/a |
Dividends & Yields
HLB bioStep does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 44.94% |
| Shareholder Yield | 44.94% |
| Earnings Yield | -35.55% |
| FCF Yield | -7.93% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on April 24, 2026. It was a reverse split with a ratio of 0.2.
| Last Split Date | Apr 24, 2026 |
| Split Type | Reverse |
| Split Ratio | 0.2 |
Scores
HLB bioStep has an Altman Z-Score of 2.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.28 |
| Piotroski F-Score | 4 |